Vernalis plc (VER) Rating Reiterated by Panmure Gordon
Vernalis plc (LON:VER)‘s stock had its “buy” rating restated by analysts at Panmure Gordon in a report issued on Thursday. They presently have a GBX 76 ($0.99) target price on the stock. Panmure Gordon’s target price would suggest a potential upside of 71.75% from the company’s current price.
Several other equities analysts have also commented on VER. Stifel Nicolaus reissued a “buy” rating on shares of Vernalis plc in a research report on Friday, June 24th. Shore Capital reissued a “house stock” rating on shares of Vernalis plc in a research report on Friday, July 8th. Finally, Canaccord Genuity reissued a “buy” rating and set a GBX 84 ($1.10) price objective on shares of Vernalis plc in a research report on Friday, July 8th. Four analysts have rated the stock with a buy rating, Vernalis plc presently has a consensus rating of “Buy” and an average target price of GBX 80.20 ($1.05).
Vernalis plc (LON:VER) opened at 45.00 on Thursday. Vernalis plc has a 52-week low of GBX 31.00 and a 52-week high of GBX 84.75. The company’s 50-day moving average is GBX 43.89 and its 200 day moving average is GBX 46.31. The company’s market cap is GBX 200.31 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/vernalis-plc-ver-rating-reiterated-by-panmure-gordon.html
Vernalis plc Company Profile
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.